Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959893 | 0.92 | KDM4E (0.33) | TDO2EGFRKDM4ELMNAALDH1A1 | |
| SCHEMBL19959900 | 0.92 | KDM4E (0.33) | TDO2EGFRKDM4ELMNAALDH1A1 | |
| SCHEMBL19959869 | 0.90 | TDO2 (0.34) | TDO2EGFRKDM4ELMNATP53 | |
| SCHEMBL19959786 | 0.88 | CYP3A4 (0.32) | KDM4ELMNAALDH1A1HPGDTP53 | |
| SCHEMBL19959887 | 0.84 | EGFR (0.32) | TDO2EGFR | |
| SCHEMBL19959906 | 0.84 | BCL2 (0.32) | TDO2EGFRKDM4ELMNAALDH1A1 | |
| SCHEMBL19959890 | 0.83 | KDM4E (0.33) | TDO2EGFRKDM4ELMNAALDH1A1 | |
| SCHEMBL19959829 | 0.83 | CYP3A4 (0.35) | KDM4ELMNAALDH1A1HPGDTP53 | |
| SCHEMBL19959897 | 0.82 | KDM4E (0.33) | TDO2EGFRKDM4ELMNAALDH1A1 | |
| SCHEMBL19965896 | 0.82 | CYP3A4 (0.35) | KDM4ELMNAALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | TDO2 1142/4885EGFR 2712/4885KDM4E 1997/4885 |
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | TDO2 1142/4885EGFR 2712/4885KDM4E 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.